15/04/2019 14:00:00

Auris Medical Receives Positive Nasdaq Listing Determination

Hamilton, Bermuda, April 15, 2019 (GLOBE NEWSWIRE) --

Hamilton, Bermuda, April 15, 2019 – Auris Medical Holding Ltd. (Nasdaq: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the Nasdaq Hearings Panel (the ''Panel'') has granted the Company’s request for the continued listing of the Company’s securities on The Nasdaq Capital Market (“Nasdaq”). The Company’s continued listing on Nasdaq is subject to the Company evidencing compliance with the minimum $1.00 bid price requirement on or before August 5, 2019.

At the hearing before the Panel, the Company presented its plan to regain compliance with the minimum bid price requirement, including the implementation of a reverse stock split if necessary. In order to demonstrate compliance with the terms of the Panel’s decision, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days on or before August 5, 2019.

About Auris Medical

Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care. The company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201). These projects have gone through two Phase 1 trials and have moved into proof-of-concept studies in 2019. In addition Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-

111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”

Forward-looking Statements

This press release may contain statements that constitute “forward-looking statements” within the meaning

of

Section

27A

of

the

Securities

Act

of

1933

and

Section

21E

of

the

Securities

Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical’s

strategies

or

expectations.

In

some

cases,

you

can

identify

these

statements

by

forward- looking

words

such

as

“may”,

“might”,

“will”,

“should”,

“expects”,

“plans”,

“anticipates”,

“believes”, “estimates”,

“predicts”,

“projects”,

“potential”,

“outlook”

or

“continue”,

or

the

negative

of

these terms

or

other

comparable

terminology.

Forward-looking

statements

are

based

on

management’s current

expectations

and

beliefs

and

involve

significant

risks

and

uncertainties

that

could

cause actual

results,

developments

and

business

decisions

to

differ

materially

from

those

contemplated by

these

statements.

These

risks

and

uncertainties

include,

but

are

not

limited

to,

Auris

Medical’s need for and ability to raise substantial additional funding to continue the development of its product

candidates,

the

ability

to

pursue

strategic

partnering

and

non-dilutive

funding

for

its

Phase 3

programs,

the

results

of

Auris

Medical’s

review

of

strategic

options

and

the

outcome

of

any

action taken

as

a

result

of

such

review,

the

timing

and

conduct

of

clinical

trials

of

Auris

Medical’s

product candidates,

the

clinical

utility

of

Auris

Medical’s

product

candidates,

the

timing

or

likelihood

of regulatory

filings

and

approvals,

Auris

Medical’s

intellectual

property

position

and

Auris

Medical’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical’s capital structure, including future

securities offerings.

These

risks

and

uncertainties

also

include,

but

are

not

limited

to,

those

described

under the caption “Risk Factors” in Auris Medical’s Annual Report on Form 20-F for the year ended December

31,

2018,

and

in

Auris

Medical's

other

filings

with

the

SEC,

which

are

available

free

of charge

on

the

Securities

Exchange

Commission's

website

at:

www.sec.gov.

Should

one

or

more

of these

risks

or

uncertainties

materialize,

or

should

underlying

assumptions

prove

incorrect,

actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Auris Medical or to persons

acting

on

behalf

of

Auris

Medical

are

expressly

qualified

in

their

entirety

by

reference

to these

risks

and

uncertainties.

You

should

not

place

undue

reliance

on

forward-looking

statements. Forward-looking

statements

speak

only

as

of

the

date

they

are

made,

and

Auris

Medical

does

not undertake any obligation to update them in light of new information, future developments or otherwise,

except

as

may

be

required

under

applicable

law.

Investor contact:

Joseph Green

Edison Advisors for Auris Medical 646-653-7030

jgreen@edisongroup.com or investors@aurismedical.com

 

logo.gif

Related content
15 Aug - 
Auris Medical Provides Business Update and Reports Firs..
30 Jul - 
Auris Medical Announces Randomization of First Patient ..
03 Jul - 
Auris Medical Completes Enrollment of Phase 1b Proof-Of..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week

Related stock quotes

Auris Medical Holding AG 2.640 -0.8% Stock price decreasing

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 August 2019 21:02:51
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190809.4 - EUROWEB3 - 2019-08-18 22:02:51 - 2019-08-18 21:02:51 - 1000 - Website: OKAY